Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Rituximab 8Cyclophosphamide 7Etoposide 5Prednisone 4Doxorubicin 4Vincristine 3Gemcitabine 3Bendamustine Hydrochloride 3prednylidene 2deltacortene 2Specimen Handling 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2CT-P10 2Busulfan 2venetoclax 1umbralisib 1ublituximab 1tebufenozide 1tafasitamab 1selinexor 1huachansu 1fludarabine phosphate 1epratuzumab 1cc-486 1Whole-Body Irradiation 1Vindesine 1VAP-cyclo protocol 1Thiotepa 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma, Large B-Cell, Diffuse × cc-486 × Clear all
NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡